Table 3.

Depressive disorder.

	Study Design	Country	No.	Age Group	Disease	Daily Dosage (g/d)	Duration	Rating Scale	End Point
Nemets et al., 2006 [76]	Randomised controlled trial	Israel	28	6–12 years	- MDD	400 mg/d EPA and 200 mg/d DHA or placebo	4 weeks	- CDRS - CDI - CGI	Highly significant effects of omega-3 on symptoms using the CDRS (p = 0.003), CDI (p < 0.005), and CGI (p = 0.002).
Young et al., 2017 [78]	Randomised controlled trial	USA	72	7–14 years	- MDD (n = 37) - dysthymic disorder (n = 5) -depressive disorder not otherwise specified (n = 30)	- 2 g/d n3-PUFAs in monotherapy - PEP in monotherapy- PEP + n3-PUFA - placebo	12 weeks	- SNAP-IV - ECBI	N-3 PUFAs yielded more favourable trajectories than placebo on the SNAP-IV Hyperactivity/Impulsivity subscale (p = 0.034, d = 0.44) and marginally more favourable on Total (p = 0.080, d = 0.42), and Inattention scores (p = 0.059, d = 0.49).
Vesco et al., 2018 [68]	Randomised controlled trial	USA	95	7–14 years	- BP-NOS or CYC (n = 23) - Depressive disorder (n = 72)	- 1.87 g/d n3-PUFAs in monotherapy - PEP monotherapy - PEP + n3-PUFAs	12 weeks	- BRIEF - GEC - BRI - YMRS	PUFAs supplementation were associated with significant improvement in executive functions and in dysphoric mood, irritability, and self-esteem.
Trebatická et al., 2020 [77]	Randomised, double-blind, placebo controlled trial	Slovakia	60	7–18 years	-MDD (n = 31) -Mixed anxiety and depressive disorder (n = 29)	2400 mg of total omega-3 PUFAs/day or placebo	12 weeks	- CDI	PUFAs supplementation were associated with reductions in Children’s Depression Inventory (CDI) scores.

BRI: Behaviour Regulation; BRIEF: Behaviour Rating Inventory of Executive Functioning; CDI: Child Development Inventory; CDRS: Children’s Depression Rating Scale; CGI Clinical Global Impressions; GEC: Global Executive Composite; ECBI: Eyberg Child Behaviour Inventory; SNAP-IV: Swanson, Nolan, and Pelham-IV.